Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

European Medicines Agency advisers said Friday that Eli Lilly’s Alzheimer’s disease treatment should not be approved, once again diverging from their U.S. counterparts. The Committee for ...

Eli Lilly has emerged as a popular growth stock thanks to its strength in the weight loss space. But the pharma giant also has an enormous opportunity in the Alzheimer's Disease market.

With approximately 101 million individuals living with diabetes, increasing access to insulin and advanced treatments is ...

Two years ago, Eli Lilly started working with Dexcom to integrate continuous glucose monitoring (CGM) into its insulin delivery devices, and it has now firmed up the alliance. Lilly has taken a ...

In honor of Equal Pay Day, PEOPLE has the exclusive first trailer for 'Lilly,' starring Patricia Clarkson Sharareh Drury is a writer on the Movies team at PEOPLE. She joined PEOPLE in 2025 and has ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Lilly's arch-rival in the diabetes category Novo Nordisk is working on its own glucose-sending insulin platform, acquired via its $800 million acquisition of UK biotech Ziylo in 2018.

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitches. The Indianapolis pharma has established an online portal to accept ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Lily Stewart ended up back in handcuffs — and with another glamorous mugshot — anyway. The University of Georgia student, is facing a second round of charges, this time for obstruction of a ...